Literature DB >> 32004971

In silico identification of potential inhibitors against human 2'-5'- oligoadenylate synthetase (OAS) proteins.

Karen J Gonzalez1, Diego M Moncada-Giraldo1, Juan B Gutierrez2.   

Abstract

As part of the type I IFN signaling, the 2'-5'- oligoadenylate synthetase (OAS) proteins have been involved in the progression of several non-viral diseases. Notably, OAS has been correlated with immune-modulatory functions that promote chronic inflammatory conditions, autoimmune disorders, cancer, and infectious diseases. In spite of this, OAS enzymes have been ignored as drug targets, and to date, there are no reports of compounds that can inhibit their activity. In this study, we have used homology modeling and virtual high-throughput screening to identify potential inhibitors of the human proteins OAS1, OAS2, and OAS3. Altogether, we have found 37 molecules that could exert a competitive inhibition in the ATP binding sites of OAS proteins, independently of the activation state of the enzyme. This latter characteristic, which might be crucial for a versatile inhibitor, was observed in compounds interacting with the residues Asp75, Asp77, Gln229, and Tyr230 in OAS1, and their equivalents in OAS2 and OAS3. Although there was little correlation between specific chemical fragments and their interactions, intermolecular contacts with OAS catalytic triad and other critical amino acids were mainly promoted by heterocycles with π electrons and hydrogen bond acceptors. In conclusion, this study provides a potential set of OAS inhibitors as well as valuable information for their design, development, and optimization.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  2’-5’- oligoadenylate synthetase (OAS); Docking; In-silico inhibition; Small drug-like molecules; Virtual screening

Year:  2020        PMID: 32004971     DOI: 10.1016/j.compbiolchem.2020.107211

Source DB:  PubMed          Journal:  Comput Biol Chem        ISSN: 1476-9271            Impact factor:   2.877


  6 in total

Review 1.  Functional Interfaces, Biological Pathways, and Regulations of Interferon-Related DNA Damage Resistance Signature (IRDS) Genes.

Authors:  Monikaben Padariya; Alicja Sznarkowska; Sachin Kote; Maria Gómez-Herranz; Sara Mikac; Magdalena Pilch; Javier Alfaro; Robin Fahraeus; Ted Hupp; Umesh Kalathiya
Journal:  Biomolecules       Date:  2021-04-22

2.  Prognostic characterization of OAS1/OAS2/OAS3/OASL in breast cancer.

Authors:  Yujie Zhang; Chaoran Yu
Journal:  BMC Cancer       Date:  2020-06-19       Impact factor: 4.430

3.  Long noncoding RNA SATB1-AS1 contributes to the chemotherapy resistance through the microRNA-580/ 2'-5'-oligoadenylate synthetase 2 axis in acute myeloid leukemia.

Authors:  Hong Zhou; Xiaofeng Jia; Fan Yang; Pengfei Shi
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

4.  Overexpression of OAS1 Is Correlated With Poor Prognosis in Pancreatic Cancer.

Authors:  Lingling Lu; Huaxiang Wang; Jian Fang; Jiaolong Zheng; Bang Liu; Lei Xia; Dongliang Li
Journal:  Front Oncol       Date:  2022-07-11       Impact factor: 5.738

5.  Development of multivariable risk signature based on four immune-related RNA-binding proteins to predict survival and immune status in lung adenocarcinoma.

Authors:  Qingsheng You; Hao Shen
Journal:  Transl Cancer Res       Date:  2022-08       Impact factor: 0.496

6.  RNA Binding Proteins as Drivers and Therapeutic Target Candidates in Pancreatic Ductal Adenocarcinoma.

Authors:  Markus Glaß; Patrick Michl; And Stefan Hüttelmaier
Journal:  Int J Mol Sci       Date:  2020-06-11       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.